Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained approval from China's National Medical Products Administration to become the marketing license holder of epalrestat tablets, according to a Hong Kong Stock Exchange disclosure on May 9.
The pharmaceutical company obtained the rights to the drug from Jiangsu Dongke Kangde Pharmaceutical in August 2023.
The drug is indicated for use in connection with diabetic neuropathy, the disclosure said.
Xinhua Pharma's Hong Kong shares closed less than 2% higher.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。